Trial site
Investigaciones Clínicas Tucumán
- 12running trials
- 5closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Conditions
- Heart failure5 trials
- Lupus (SLE)5 trials
- Obesity5 trials
- Chronic kidney disease3 trials
- Type 2 diabetes3 trials
- Coronary artery disease2 trials
- Stroke2 trials
- Type 1 diabetes2 trials
- Atrial fibrillation1 trial
- Peripheral artery disease1 trial
- Phase
- Phase 313 trials
- Phase 23 trials
- Phase 2/31 trial
- Status
- Active, not recruiting7 trials
- Completed4 trials
- Recruiting4 trials
- Enrolling by invitation1 trial
- Terminated1 trial
- Lead sponsor
- Eli Lilly and Company7 trials
- Biogen3 trials
- Boehringer Ingelheim2 trials
- Janssen Research & Development, LLC2 trials
- Amgen1 trial
- and 2 more
Running trials
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Active, not recruiting
Active, not recruiting
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Active, not recruiting
Enrolling by invitation
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Heart failure3 recruiting
- Chronic kidney disease1 recruiting
- Lupus (SLE)1 recruiting
- Obesity1 recruiting
- Stroke1 recruiting
Closed trials
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Completed
Terminated
Completed
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
Completed
Site data: ClinicalTrials.govUpdated 19 Nov 2026